Advocacy intelligence hub — real-time data for patient organizations
Emory University — PHASE1
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. — PHASE2, PHASE3
National Health Research Institutes, Taiwan — PHASE1, PHASE2
Novartis Pharmaceuticals — PHASE3
Mainline Biosciences (Shanghai) Co., Ltd — PHASE1, PHASE2
University Hospital, Strasbourg, France
Vanderbilt-Ingram Cancer Center — PHASE4
Lutathera: FDA approved
treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors
Assistance Publique - Hôpitaux de Paris — NA
Jiangsu HengRui Medicine Co., Ltd. — PHASE3
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Lutathera
Advanced Accelerator Applications
Lutathera
(lutetium Lu 177 dotatate)Orphan drugAdvanced Accelerator Applications
12.1 Mechanism of Action Lutetium Lu 177 dotatate binds to somatostatin receptors with highest affinity for subtype 2 somatostatin receptors (SSTR2). ...
Somatuline Depot
(Lanreotide)Orphan drugstandardIPSEN, Inc.
12.1 Mechanism of Action Lanreotide, the active component of SOMATULINE DEPOT is an octapeptide analog of natural somatostatin. The mechanism of actio...
Browse all Gastroenteropancreatic neuroendocrine neoplasm news →
Urielle Desalbres
AP-HM
Nageshwara V Dasari, MD
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Jianming Xu
Chinese PLA General Hospital
Alain Hendlisz, MD
Jules Bordet Institute
Ghoufrane TLILI
University Hospital, Bordeaux
Amélie Deleporte, MD
Jules Bordet Institute
View all Gastroenteropancreatic neuroendocrine neoplasm specialists →